



ASX ANNOUNCEMENT

## **NANOCELLE® NASAL RNA (NUCLEIC ACID) PROGRAM ENTERS FINAL STAGES**

**Sydney, November 10, 2022** - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, in collaboration with Prof. Daniela Traini's team from Macquarie University and Woolcock Institute of Medical Research and Prof. Pall Thordarson's team from UNSW Sydney's RNA Institute, is excited to announce that the Nasal RNA program is entering the final phase of development.

Funded by a NSW Govt. grant and as part of the Government's future antiviral/vaccine response, the program brought together three teams to determine the viability of a concept product: a nanoparticle RNA delivered nasally, featuring Medlab's patent protected NanoCelle®.

The earlier stages of this project have been completed, which were to perform feasibility studies using insulin. Insulin was chosen due to being a water-soluble biological molecule, traits shared with RNA, and which differentiate it from the small lipophilic molecules that have been the main subject of NanoCelle® technology.

The collaboration succeeded in:

- (i) encapsulating insulin with NanoCelle® technology
- (ii) demonstrating that NanoCelle® encapsulated biological molecules were suitable for nasal delivery
- (iii) moving nasal spray delivered insulin one step closer along the translational pathway to commercialisation

Dr. Chung Wong and Prof. Daniela Traini will present this work at a conference in Edinburgh (UK) in December 2022 (Drug Delivery to the Lungs Conference 2022).

The final phase of the program (per the grant agreement) is around the RNA encapsulation in NanoCelle® and this will commence at Medlab's laboratories in UNSW Sydney. This final step requires various approvals before the encapsulation process can start.

Subject to approvals for final phase commencement, optimistically a viability determination is likely before Christmas.

**ENDS**

**Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

**About Medlab Clinical:**

Medlab Clinical Ltd (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit [www.medlab.co](http://www.medlab.co) *Medlab – better medicines, better patient care*

Medlab Clinical Ltd  
Dr. Sean Hall  
T: +61 411 603 378  
E: [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)